Tate & Lyle enters ingredients partnership with enzyme company Zymtronix
The partnership aims to leverage novel enzyme immobilisation technologies that improve the productivity and sustainability of ingredient manufacturing.
Zymtronix’s enzyme immobilisation platform is said to help transform ingredient manufacturing by improving the productivity of biocatalysis. This is achieved through the immobilisation of enzymes onto magnetic metamaterials to increase the efficiency and sustainability of enzyme-based industrial processes.
Tate & Lyle’s investment in Zymtronix aims to enable the company to improve and innovate upon their technology, with the goal of scaling up their platform to support process scale production. Zymtronix is initially working with Tate & Lyle to improve the use of enzymes in the production of certain ingredients and improve cost efficiency.
“Consumers worldwide are looking for healthier food and drink, and we are proud to have the ingredients to help deliver just that. Improving lives for generations is at the heart of what we do, so we are excited to harness the power of Zymtronix’s enzyme immobilisation platform, which will make our manufacturing processes more efficient. The platform also has the potential to accelerate our ability to make our ingredient solutions accessible to more consumers,” said Andrew Taylor, President of Innovation and Commercial Development, Tate & Lyle.
“We are delighted to announce Tate & Lyle as our first corporate partner. Their investment will enable us to further scale up our enzyme immobilisation technology, advance our processes, develop our own target ingredients, and grow our team,” said Stéphane Corgié, Founder and CEO-CTO, Zymtronix.